Skip to main content
. 2020 Feb 28;4(2):83–90. doi: 10.7150/ntno.43808

Figure 6.

Figure 6

Effect of OMB formulation and size on pharmacokinetic parameters for contrast persistence in vivo. A) Mean half-lives of 0.5-2, 2-10 µm DBPC; and 0.5-2, 2-10 µm DSPC OMBs. B) Maximum ultrasound contrast intensity for each OMB formulation. C) AUC for each OMB formulation based on the pharmacokinetic model fit to the TIC. Statistical significance indicated for p < 0.05 (*) and p < 0.01 (**).